Loading patent…
AssigneesInstitut National de la Sante et de la Recherche Medicale, Universite De Rennes, École des Hautes Études en Santé Publique, Etablissement Francais Du Sang (Efs), Chu De Rennes
InventorsFrédéric CHALMEL, Judikael SAOUT, Gwendoline LECUYER, Nathalie RIOUX, Simon LEONARD, Aurélie LARDENOIS, Bertrand EVRARD
Estimating the term…
The present invention pertains to a method for the prognosis or clear cell renal cell carcinoma (ccRCC) based on cell clusters identified by deconvolution of a single-cell malignancy atlas. The present inventors have designed and validated a scRNA-seq protocol to characterize the malignant cells (MC) in ccRCC tumors from ccRCC patients. By applying an in silico deconvolution approach 5 to a bulk RNA-seq dataset of ccRCCs, the present inventors have shown that the predicted proportion of specific cells clusters were strongly associated with specific prognoses and notably allow for the accurate stratification of patients. The markers identified by the present inventors particularly allow identifying high-grade patients who would have erroneously been classified as low-grade according to the current classification system.
A method for treating clear cell renal cell carcinoma (ccRCC) in a patient, said method comprising the following steps:
Dependencies are inferred from the claim text.